英夫利昔单抗联合健脾补肾活血中药汤剂治疗类风湿关节炎疗效及安全性观察

[目的]探讨英夫利昔单抗联合健脾补肾活血中药汤剂治疗类风湿关节炎的疗效及安全性。[方法]60例类风湿关节炎患者随机分为两组,对照组使用英夫利昔单抗联合甲氨蝶呤治疗,试验组使用英夫利昔单抗联合甲氨蝶呤联合中药治疗。治疗前后分别记录关节疼痛数,关节肿胀数,晨僵时间,疼痛视觉模似评分法(VAS)评分,健康评估问卷(HAQ)评分,实验室检查血沉(ESR)、C-反应蛋白(CRP);安全指标血尿便常规及肝功能。并记录患者症状体征及中医证候评分。[结果]两组治疗后均较治疗前有明显改善,差异有统计学意义(P0.05);两组疗效相当,组间差异无统计学意义(P0.05),不良反应试验组少于对照组,差异有统计学意义(P0.05)。[结论]联合中药治疗在不影响治疗效果的前提下能明显降低药物不良反应,提高患者依从性。

Observed the clinical efficacy and safety of Infliximab combined with Jianpi Bushen Huoxue decoction in treating rheumatoid arthritis

[Objective] To investigate the efficacy and safety of infliximab combined with Jianpi Bushen Huoxue decoction in treating rheumatoid arthritis.[Methods] Sixty patients with rheumatoid arthritis were randomly divided into two groups, the control group using infliximab combined with methotrexate treatment, the test group using infliximab combined with methotrexate and decoction treatment. Before and after treatment were recorded number of joint pain, joint swelling count, morning stiffness, pain VAS scores, HQA scores, laboratory parameters such as ESR, CRP; safety indicators such as blood cell analysis, routine urine, stool routine, liver function. And record signs and symptoms syndromes score.[Results] After treatment than before treatment significantly improved, the difference was statistically significant(P<0.05); the efficacy between the two groups was not statistically significant (P>0.05), adverse reaction of the test group is less than the control group, the difference was statistically significant (P<0.05).[Conclusion] Combined treatment of traditional Chinese medicine under the premise does not affect the treatment can significantly reduce adverse drug reactions, and improve patient compliance.